[A23-105] Bimekizumab (psoriatic arthritis) – Addendum to Commission A23-60

Last updated 21.12.2023

Project no.:
A23-105

Commission:
Commission awarded on 07.11.2023 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Muscles, bones and joints

Indication:

Active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to prior disease-modifying antirheumatic therapy

Result of dossier assessment:

Patients who have had an inadequate response or who have been intolerant to prior conventional disease-modifying antirheumatic therapy:Unchanged after addendum: added benefit not proven
Patients who have had an inadequate response or who have been intolerant to prior therapy with biologic disease-modifying antirheumatic drugs:Unchanged after addendum: added benefit not proven

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

DOI:

https://dx.doi.org/10.60584/A23-105